ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ:RARE) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07.Submission of Matters to a Vote of Security Holders.

On June 22, 2017, Ultragenyx Pharmaceutical Inc. (the Company)
held its Annual Meeting of Stockholders (the Annual Meeting). As
of the record date of April 24, 2017, 42,282,287 shares of the
Companys common stock were outstanding and entitled to vote at
the Annual Meeting. A total of 40,260,307 shares of the Companys
common stock were represented in person or by proxy at the Annual
Meeting.

Proposal No. 1 Election of Class I Directors

At the Annual Meeting, the Companys stockholders elected the
Class I director nominees below to the Companys Board of
Directors to hold office until the 2020 Annual Meeting of
Stockholders or until their successors are elected. The votes on
Proposal 1 were as follows:

Proposal No. 2 Ratification of Selection of Independent
Registered Accounting Firm

At the Annual Meeting, the Companys stockholders ratified the
selection of Ernst Young LLP as the independent registered public
accounting firm of the Company for its fiscal year ending
December 31, 2017. The votes on Proposal 2 were as follows:

Proposal No. 3 Advisory (Non-Binding) Vote to Approve Executive
Compensation

At the Annual Meeting, the Companys stockholders voted, on an
advisory basis, in favor of a resolution approving the
compensation the Company pays to its named executive officers as
described in the Proxy Statement. The votes on Proposal 3 were as
follows:

* * *

-2-

About ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ:RARE)

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. Recombinant human beta-glucuronidase (rhGUS), is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7 (MPS 7). It is developing UX007 for oral administration intended as a substrate replacement therapy. It is developing aceneuramic acid extended-release (Ace-ER) for the treatment of GNE myopathy.